NanoString Technologies Announces Favorable Draft Local

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
NanoString Technologies Announces Favorable Draft Local Coverage Determination by Palmetto GBA for Its Prosigna Breast Cancer Assay

SEATTLE, May 14, 2015 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses molecular diagnostic technologies through its MolDx program, has issued a favorable draft local coverage determination (LCD) for the Prosigna Breast Cancer Assay.

"We are encouraged by the draft Local Coverage Determination published today by Palmetto's MolDx team," said Brad Gray, President and Chief Executive Officer of NanoString Technologies. "We are continuing to make progress toward our vision of ensuring that U.S. breast cancer patients have access to the best diagnostic technology, and this progress builds on the momentum of Prosigna's recent inclusion in the St. Gallen International Breast Cancer Guidelines."

The draft LCD, which proposes the coverage policy for Medicare beneficiaries, includes reimbursement coverage for postmenopausal patients with ER+, lymph node-negative, stage I or II breast cancer; and ER+, lymph node-positive (1-3 positive nodes), stage II breast cancer. The draft LCD is posted to the Medicare Coverage Database on the Centers for Medicare & Medicaid Services (CMS) website at: http://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=36124&ContrId=225&ver=5&ContrVer=1&Cntrctr=All&UpdatePeriod=624&bc=AQAAEAAAAAAAAA%3d%3d&.

Under Medicare rules, the draft LCD is subject to a minimum 45-day public comment period, which will begin on June 9th and end on July 24th. After the public comment period, Palmetto GBA will review public comments and finalize the draft coverage policy.  When finalized and published, the decision becomes effective after a minimum notification period of 45 days.  The draft LCD applies to the J11 jurisdiction, comprising North Carolina, South Carolina, Virginia and West Virginia. Other Medicare jurisdictions participating in the MolDx program may choose to adopt the same coverage policy.

About the Prosigna® Breast Cancer Prognostic Gene Signature Assay and nCounter® Dx Analysis System


The Prosigna Assay provides a risk category and numerical score for assessment of the risk of distant recurrence of disease at 10 years in postmenopausal women with node-negative (Stage I or II) or node-positive (Stage II), hormone receptor-positive (HR+) breast cancer. Based on the PAM50 gene signature initially discovered by Charles Perou, Ph.D. and colleagues, the Prosigna Assay is an in vitro diagnostic tool that utilizes gene expression data weighted together with clinical variables to generate a risk category and numerical score to assess a patient's risk of distant recurrence of disease. The Prosigna Assay measures gene expression levels of RNA extracted from formalin-fixed paraffin embedded (FFPE) breast tumor tissue previously diagnosed as invasive breast carcinoma. 



The Prosigna Assay requires minimal hands-on time and runs on NanoString's proprietary nCounter® Dx Analysis System, which offers a reproducible and cost-effective way to profile many genes simultaneously with high sensitivity and precision.


The nCounter Dx Analysis System is a highly automated and easy-to-use platform that utilizes a novel digital barcoding chemistry to deliver high precision multiplexed assays. The system is available in the multi-mode FLEX configuration, which is designed to meet the needs of high-complexity clinical laboratories seeking a single platform with the flexibility to run the Prosigna Breast Cancer Assay and, when operated in the "Life Sciences" mode, process translational research experiments and multiplexed assays developed by the laboratory.

In the United States, the Prosigna Assay is available for diagnostic use when ordered by a physician. The Prosigna Assay has been CE-marked and is available for use by healthcare professionals in the European Union and other countries that recognize the CE Mark, as well as Canada, Israel, Australia, New Zealand and Hong Kong.

In the U.S., the Prosigna Assay is indicated in female breast cancer patients who have undergone surgery in conjunction with locoregional treatment consistent with standard of care, either as:

(1) a prognostic indicator for distant recurrence-free survival at 10 years in postmenopausal women with Hormone Receptor-Positive (HR+), lymph node-negative, Stage I or II breast cancer to be treated with adjuvant endocrine therapy alone, when used in conjunction with other clinicopathological factors or (2) a prognostic indicator for distant recurrence-free survival at 10 years in postmenopausal women with Hormone Receptor-Positive (HR+), lymph node-positive (1-3 nodes), Stage II breast cancer to be treated with adjuvant endocrine therapy alone, when used in conjunction with other clinicopathological factors. The device is not intended for patients with four or more positive nodes.

For more information, please visit www.prosigna.com.

About NanoString Technologies, Inc.

NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in over 700 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology has also been applied to diagnostic use. The Prosigna Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer.

For more information, please visit www.nanostring.com.

The NanoString Technologies logo, NanoString, NanoString Technologies, nCounter, and Prosigna are registered trademarks or trademarks of NanoString Technologies, Inc. in various jurisdictions.  

Leigh Salvo of Westwicke Partners 415-513-1281

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Avelo Tests Loyalty Math With WeSalute Fare Discounts

Updated Category News Views 237

Airline discounts can look like generosity until the load factor starts talking back. Avelo Airlines has joined WeSalute with fare discounts for active-duty military members, veterans, first responders, nurses, medical professionals, public servants, teachers and eligible family members. It is a sensible move for a young carrier built around smaller airports and lower...

Continue Reading
ZTO's Pricing Muscle Shows Up in Third-Quarter Results

Updated Category News Views 136

Ten billion parcels can hide plenty of ugly economics, but ZTO's third quarter does not look like a volume-at-any-cost stunt. The company moved 10.241 billion parcels, up 7.0% from a year earlier, and says that outpaced the industry by 4.1 percentage points. More importantly, revenue climbed 21.0% to RMB14.36 billion while adjusted net income reached RMB2.57 billion. That...

Continue Reading
GALLS Honors Service With Lexington Hall of Fame Wall

Updated Category News Views 86

A headquarters wall can say more about a company than another polished mission statement ever will. On November 17, 2026, GALLS® unveiled the National Law Enforcement Officer Hall of Fame Wall at its Lexington, Kentucky, corporate headquarters, displaying portraits of every past inductee into the National Law Enforcement Officer Hall of Fame. Recognition, made permanent...

Continue Reading
Floating Solar Gets a Serious Test in Central New York

Updated Category News Views 86

A flooded quarry pit outside Cortlandville is getting a second career, and that is more interesting than another solar announcement draped across empty acreage. Third Pillar Power has started construction on Crown City Solar at Suit-Kote Corporation's active Polkville Crushed Stone Facility, pairing a working mine, asphalt plant, and storage terminal with what the...

Continue Reading
Exiger's CEO Honored for Military Support Excellence

Updated Category News Views 58

Recognizing Civilian and Military Leadership When you hear "recognition in the military sector," it isn't just a pat on the back. It's a whole parade of brass hats and high-flyers giving their nods. So, November 10th wasn't just any regular day—Brandon Daniels, CEO of Exiger, gets a shiny, prestigious Five-Star Award for his "extraordinary support" of our military...

Continue Reading
Sola's 11-Step Push Makes Salon Ownership Less Blind

Updated Category News Views 115

A pristine studio does not pay rent by itself. That is the uncomfortable little truth sitting underneath Sola Salons’ new 11-step roadmap for beauty professionals considering salon-suite ownership. The company is telling stylists, estheticians, nail technicians, massage therapists, and other independent operators to treat the move from commission work to ownership like...

Continue Reading
STORMER LAT Targets Sewer Crews' Costly Access Delays

Updated Category News Views 32

A buried cleanout can turn a simple sewer inspection into a scheduling circus. That unglamorous headache is exactly where FIBERSCOPE is aiming its new STORMER LAT Lateral Launch Camera System, announced November 17, 2026. This is not some flashy consumer gadget hunting for attention; it is field equipment built around a painfully ordinary municipal problem: crews often...

Continue Reading
Voltage Energy's Microgrid Launches at RE+ 2026

Updated Category News Views 147

Voltage Energy Unveils New Power Systems In the swirling chaos of energy innovation, Voltage Energy is trying to carve its path at the heart of RE+ 2026. Out in Las Vegas, amidst the buzz of renewable energy tech, they introduced their Microgrid System (MGS) along with two new electrical balance of system (EBOS) products—the Load Break Disconnect Box (LBD) and Combiner...

Continue Reading
Stand Out For Good Makes a Bold Michigan Avenue Bet

Updated Category News Views 183

A six-floor retail commitment lands with a thud Stand Out For Good is taking on roughly 51,079 square feet at 669 North Michigan Avenue, and nobody should mistake that for a casual expansion. Six levels on Chicago's Magnificent Mile is a proper declaration of intent, especially in a retail district that has endured plenty of empty-window handwringing and big-brand churn....

Continue Reading
Medical School Rejections Carry a Steep Price Tag Too

Updated Category News Views 107

A rejection letter can turn into a remarkably expensive piece of paper. BeMo Academic Consulting's new Medical School Admissions Trends Report argues that the damage from missing medical-school admission goes far beyond bruised confidence: applicants can spend thousands chasing another cycle, lose time entering practice, and, if they never get in, forgo what the report...

Continue Reading

Top 5 Most Recently Viewed Articles

Coway's Inverter Dehumidifier 23L Triumphs at Global Design Awards

Updated Category News Views 208

Inverter Dehumidifier 23L Wins Recognition at Good Design Awards - The Inverter Dehumidifier 23L gains accolades for its compact design and user-friendly features at the Good Design Awards 2025. - This recent achievement cements Coway's status as a leading player in global design, recognized by all four major awards this year. Coway's Prestigious Award Recognition Hosted...

Continue Reading
Veru's Enobosarm & Semaglutide: A New Era in Weight Loss Safety

Updated Category News Views 314

Positive Safety Profile from Veru's Clinical Study Veru Inc. (NASDAQ: VERU), a trailblazer in biopharmaceuticals, recently revealed exciting topline safety results from its Phase 2b QUALITY clinical study. This trial examined the combination of enobosarm and semaglutide, uncovering significant advantages in safety and efficacy compared to semaglutide alone. Understanding...

Continue Reading
How a $1000 Investment in REV Group Can Grow Over Time

Updated Category News Views 180

Understanding REV Group's Market Performance REV Group (NYSE: REVG) has demonstrated impressive performance in the stock market over the past five years. This company has not only outperformed the broader market, but it has done so by a remarkable 29.45% on an annualized basis, resulting in an average annual return of 42.83%. With a market capitalization reaching...

Continue Reading
Castellum's GTMR Achieves Key CMMI Level 3 Milestone

Updated Category News Views 172

Castellum's GTMR Achieves Key CMMI Level 3 Milestone Castellum, Inc. (NYSE-American: CTM) has exciting news to share, as it announces its subsidiary, Global Technology and Management Resources, Inc. (GTMR), has achieved a significant milestone by obtaining a Level 3 appraisal under ISACA’s Capability Maturity Model Integration (CMMI). This recognition highlights GTMR's...

Continue Reading
Discovering Nature Close Up: The MicroCam X1 Launch

Updated Category News Views 162

Introducing the MicroCam X1 by Littpopo Littpopo, an innovative brand dedicated to exploration technology, has launched the MicroCam X1, a remarkable pocket microscope camera now live on a crowdfunding platform. This unique device combines a powerful 400X microscope with a 4K camera, making it an essential tool for educators, content creators, families, and adventurers...

Continue Reading